Until recently, microbicide research has focused on vaginal microbicides. Recent initiatives and ongoing studies highlight the need for safe and effective rectal microbicides as part of an essential HIV prevention toolkit.
Ready, Set, Rectal Microbicides: An Update on Rectal Microbicide Research and Advocacy
Community-driven strategies for the use of antiretrovirals as prevention: United States Workshop Report
Launched in 2011, the multi-national Mapping Pathways project provides a community-led, research-driven, multi-layered synthesis about the use of antiretroviral-based prevention strategies. Project partners included RAND, AIDS Foundation of Chicago, AIDS United, Desmond Tutu HIV Foundation, Naz India, and Bairds CMC.
In the latter half of 2013, a subset of the Mapping Pathways team from RAND Europe and AIDS Foundation of Chicago conducted a series of three “knowledge exchange” scenario development workshops with a focus on the United States, held in San Francisco, California; Atlanta, Georgia; and Washington, DC. The aim of the workshops was to further share the findings of the report and to continue enhancing the community-driven, locally informed approach to the wider evidence base for ARV-based prevention. This report summarizes the outputs of those three workshops.
Mapping Pathways: Developing evidence-based, people-centred strategies for the use of antiretrovirals as prevention
Mapping Pathways is a multinational project to develop and nurture a research-driven, community-led global understanding of the emerging evidence base around the adoption of antiretroviral (ARV)-based prevention strategies to end the HIV/AIDS epidemic. The project is based on the premise that the current array of prevention options is not sufficient; new pathways to prevention, based on enhanced assessment and analysis of likely impact, are needed to address new infections adequately.
AIDS Vaccine Research: An overview
This series of infographics highlights the current state of the field. Each research area is expanded with key details about the current focus and advancements in the science along with critical issues that advocates should be tracking.
HIV Vaccines by the Numbers: Trials, discoveries, money and more
We know that an AIDS vaccine is possible and that a vaccine will be an important part of a long-term strategy to end the AIDS epidemic. The road ahead is long, but clinical trials—even those with disappointing results—and early-stage research provide critical clues to the way forward. This graphics represents key facts about the AIDS vaccine field.
AIDS Vaccine Science for Busy Advocates – Current AIDS Vaccine R&D Pipeline
One-pager reviewing what we’ve learned from previous efficacy trials, the product pipeline and where we are today and future directions toward finding a vaccine that works.
AIDS Vaccine Science for Busy Advocates – RV144: Building on a breakthrough
A one-page document describing RV144, the first AIDS vaccine trial to show protection against HIV in humans, and plans to further this research.
AIDS Vaccine Science for Busy Advocates – Passive Immunization: An important piece of the puzzle
A one-page document describing passive immunization, the transfer of pre-made antibodies, and its potential for HIV prevention.
HIV Vaccines: Key messages
This is a three-page document providing main points surrounding vaccine research. For a shorter one-page version of this, click here.
Pre-Exposure Prophylaxis: An introductory factsheet
This introductory 2-page document defines PrEP, reviews the scientific evidence to date, and outlines key research, regulatory and advocacy issues going forward. This factsheet is part of a series on emerging HIV prevention strategies.